OM
IRD

Opaleye Management’s Opus Genetics IRD Stock Holding History

Opaleye Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Buy
1,125,000
+5,000
+0.4% +$23.3K 0.42% 36
2026
Q1 		$2.25M Hold
1,120,000
– – 0.3% 43
2025
Q4 		$2.25M Buy
1,120,000
+20,000
+2% +$40.6K 0.3% 43
2025
Q3 		$1.81M Sell
1,100,000
-120,000
-10% -$149K 0.26% 35
2025
Q2 		$1.15M Buy
1,220,000
+45,000
+4% +$41.7K 0.23% 36
2025
Q1 		$1.55M Buy
+1,175,000
New +$1.31M 0.34% 36

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Opaleye Management's IRD Position: Q2 2026 in Review

Opaleye Management increased its Opus Genetics (IRD) stake by 0.45% in Q2 2026, buying an estimated $23.3K and bringing the position to 1,125,000 shares worth $4.62M. The position accounts for 0.42% of the portfolio, ranked #36.

Opaleye Management first reported a position in IRD in Q1 2025 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Opaleye Management held 1,125,000 shares of Opus Genetics worth $4.62M as of Q2 2026.
  • Opaleye Management bought 5,000 Opus Genetics shares in Q2 2026, an estimated $23.3K.
  • Opus Genetics made up 0.42% of Opaleye Management's portfolio in Q2 2026, its #36 holding.
  • Opaleye Management first reported a position in Opus Genetics in Q1 2025 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.